GO:1902515 thioredoxin-disulfide reductase complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902515 (thioredoxin-disulfide reductase complex) is a cellular_component term defined as a protein complex capable of thioredoxin-disulfide reductase activity.
• The complex catalyzes the NADPH-dependent reduction of oxidized thioredoxin, a central node in cellular redox homeostasis and antioxidant defense.
• Thioredoxin reductase 1 (TXNRD1) is the principal selenoprotein subunit of this complex in mammalian cells and is a validated anticancer target.
• Pharmacological inhibition of thioredoxin-disulfide reductase complexes has been extensively patented and explored for cancer therapy.
• Loss of thioredoxin reductase function sensitizes glucose-starved glioblastoma cells to disulfidptosis and modulates ferroptosis via GPX4.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect the causal roles of thioredoxin-disulfide reductase complex genes in disease.
Description
The thioredoxin system is a fundamental antioxidant and redox-regulatory machinery present in all living cells. At its core lies the thioredoxin-disulfide reductase complex (GO:1902515), a protein assembly that catalyzes the NADPH-dependent reduction of oxidized thioredoxin. This complex maintains the reduced state of thioredoxin, which in turn serves as an electron donor for peroxiredoxins, ribonucleotide reductase, and numerous transcription factors. The QuickGO definition states that GO:1902515 is 'A protein complex which is capable of thioredoxin-disulfide reductase activity.' Because redox imbalance underlies cancer, neurodegeneration, and infectious disease, researchers increasingly target this complex for therapeutic intervention. The mammalian thioredoxin-disulfide reductase complex is best characterized by its selenoprotein subunit TXNRD1, which contains a conserved C-terminal selenocysteine residue essential for catalytic efficiency. Structural and mechanistic studies have revealed that the complex operates through a coordinated electron transfer chain from NADPH to FAD to an N-terminal cysteine pair and finally to the C-terminal selenocysteine-cysteine motif. This architecture makes the complex uniquely vulnerable to electrophilic and metal-based inhibitors, a property that has been exploited in anticancer drug discovery. Despite its importance, the thioredoxin-disulfide reductase complex remains understudied in the context of precise gene editing. Most functional data come from pharmacological inhibition or RNA interference, which lack the allelic resolution needed to separate catalytic from scaffolding functions. CRISPR-based models now offer a path to define the causal contribution of each complex subunit to redox signaling, cell death, and disease progression. This article synthesizes the current understanding of GO:1902515, its genes, regulation, disease links, and the experimental methods used to study it.
thioredoxin-disulfide reductase complex At A Glance
| GO ID | GO:1902515 |
|---|---|
| GO term | thioredoxin-disulfide reductase complex |
| Ontology | cellular_component |
| Synonym | None listed in QuickGO |
| Major function | NADPH-dependent reduction of oxidized thioredoxin |
| Catalytic cofactor | FAD; redox-active cysteine and selenocysteine residues |
| Subcellular location | Cytoplasm and mitochondria (isoform-dependent) |
| Representative subunit | TXNRD1 (thioredoxin reductase 1) |
| Disease relevance | Cancer, neurodegeneration, infectious disease, ferroptosis/disulfidptosis |
What Is GO:1902515?
GO:1902515, thioredoxin-disulfide reductase complex, is a cellular_component term describing a protein complex that possesses thioredoxin-disulfide reductase activity. In practical terms, this complex uses reducing equivalents from NADPH to convert oxidized thioredoxin (thioredoxin disulfide) back to its reduced dithiol form. The complex typically includes a flavoprotein subunit with FAD and redox-active cysteine residues, and in mammals often a selenocysteine-containing subunit. By maintaining the reduced thioredoxin pool, the complex supports antioxidant defense, DNA synthesis, and redox-sensitive signaling.
Why Is thioredoxin-disulfide reductase complex Important in Cell Biology?
The thioredoxin-disulfide reductase complex is a central hub for cellular redox homeostasis and a validated target in oncology and beyond. Its activity controls the reduced state of thioredoxin, which directly influences peroxiredoxin-mediated peroxide detoxification, ribonucleotide reductase-dependent DNA synthesis, and the activity of redox-sensitive transcription factors. Pharmacological inhibition of this complex has been pursued for over two decades, with numerous patents covering small molecules, metal complexes, and selenium-based compounds. More recently, genetic and pharmacological studies have linked thioredoxin reductase 1 to ferroptosis and disulfidptosis, two emerging forms of regulated cell death with therapeutic potential in glioblastoma and other cancers. Understanding GO:1902515 is therefore essential for researchers in cancer biology, redox signaling, and drug discovery.
• Maintains the reduced thioredoxin pool required for peroxiredoxin and methionine sulfoxide reductase activities.
• Supports DNA synthesis by providing reducing equivalents to ribonucleotide reductase.
• Modulates ferroptosis by influencing GPX4 expression and lipid peroxide handling.
• Mediates disulfidptosis sensitivity in glucose-starved cancer cells.
• Is a validated target for anticancer metal complexes and electrophilic inhibitors.
• Plays a role in host-pathogen interactions, as suggested by tuberculosis genome studies.
• Contributes to mitochondrial redox balance and apoptosis regulation.
• Represents a patent-rich area for therapeutic development.
• Its selenoprotein nature links it to selenium metabolism and nutritional status.
• Offers opportunities for CRISPR-based causal inference in disease models.
Core Biology of GO:1902515
What Happens During thioredoxin-disulfide reductase complex?
In simple terms: The complex acts like a molecular battery charger, using NADPH to recharge oxidized thioredoxin back to its active reduced form.
The thioredoxin-disulfide reductase complex catalyzes the transfer of electrons from NADPH to oxidized thioredoxin. The flavin adenine dinucleotide (FAD) cofactor accepts hydride from NADPH, and electrons are relayed through redox-active cysteine residues to the C-terminal selenocysteine-cysteine motif, which finally reduces the thioredoxin disulfide. This reaction is essential for maintaining the reduced state of thioredoxin, which then reduces peroxiredoxins and other target proteins.
Structure and Composition of thioredoxin-disulfide reductase complex
In simple terms: The complex is built from a large flavoprotein subunit that holds FAD and a selenium-containing tail, often working as a dimer.
In mammals, the best-characterized thioredoxin-disulfide reductase complex is a homodimer of TXNRD1, a selenoprotein with an N-terminal FAD-binding domain, an NADPH-binding domain, and a C-terminal selenocysteine-cysteine redox center. Each monomer contains a conserved Cys-Val-Asn-Val-Gly-Cys motif that participates in electron transfer. The selenocysteine residue is encoded by a UGA codon and requires a dedicated selenocysteine insertion machinery. Mitochondrial isoforms (TXNRD2) share similar architecture but differ in localization and substrate specificity.
Molecular Mechanism of thioredoxin-disulfide reductase complex
In simple terms: Electrons flow from NADPH to FAD to cysteine pairs and finally to thioredoxin, driven by a selenium-containing tail.
The catalytic cycle begins with NADPH binding and hydride transfer to FAD, forming FADH2. Electrons are then passed to the N-terminal cysteine pair (Cys59 and Cys64 in TXNRD1), which reduces the C-terminal selenocysteine-cysteine motif. This motif then reduces the disulfide bond in oxidized thioredoxin. The selenocysteine lowers the pKa of the adjacent cysteine, accelerating the reaction. Inhibitors such as gold(III) complexes and chiral compounds covalently modify the selenocysteine or cysteine residues, blocking electron transfer.
Regulation of thioredoxin-disulfide reductase complex
In simple terms: The complex is controlled by how much enzyme is made, how much NADPH is available, and by oxidative stress that can modify its active site.
Thioredoxin-disulfide reductase complex activity is regulated at multiple levels. Transcriptional regulation of TXNRD1 is influenced by Nrf2 and other stress-responsive factors. Post-translational modifications, including oxidation of the selenocysteine residue, can reversibly inactivate the enzyme. Substrate availability, particularly NADPH levels, also limits flux through the complex. In cancer cells, TXNRD1 is often overexpressed to cope with elevated oxidative stress, making it a therapeutic vulnerability.
Role in Ferroptosis and Disulfidptosis
In simple terms: When the complex fails, cells can die through iron-dependent lipid peroxidation (ferroptosis) or disulfide stress (disulfidptosis).
Recent studies show that TXNRD1, the catalytic subunit of the thioredoxin-disulfide reductase complex, promotes ferroptosis by suppressing GPX4 expression, revealing a non-canonical role in cell death regulation. Conversely, inhibition of TXNRD1 sensitizes glucose-starved glioblastoma cells to disulfidptosis, a newly described cell death modality triggered by disulfide stress. These findings position the complex at the intersection of redox metabolism and regulated cell death, with implications for cancer therapy.
Key Genes Involved in GO:1902515 thioredoxin-disulfide reductase complex
The following genes encode subunits, regulators, and related proteins of the thioredoxin-disulfide reductase complex and its redox network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TXNRD1 | Cytosolic thioredoxin reductase; catalytic subunit of the complex | Primary target in cancer; linked to ferroptosis and disulfidptosis |
| TXNRD2 | Mitochondrial thioredoxin reductase | Mitochondrial redox balance; apoptosis regulation |
| TXN | Thioredoxin; substrate of the complex | Redox signaling; antioxidant defense |
| TXN2 | Mitochondrial thioredoxin | Mitochondrial redox homeostasis |
| PRDX1 | Peroxiredoxin; reduces peroxides using reduced thioredoxin | Antioxidant defense; cancer progression |
| PRDX3 | Mitochondrial peroxiredoxin | Mitochondrial peroxide detoxification |
| GPX4 | Glutathione peroxidase 4; lipid peroxide repair | Ferroptosis regulation; suppressed by TXNRD1 |
| SLC7A11 | Cystine/glutamate antiporter; supports glutathione synthesis | Disulfidptosis sensitivity; ferroptosis |
| NFE2L2 | Nrf2; transcription factor regulating antioxidant genes | Transcriptional control of TXNRD1 |
| SEPHS2 | Selenophosphate synthetase; selenocysteine synthesis | Selenoprotein maturation for TXNRD1 |
| EEFSEC | Selenocysteine-specific elongation factor | Selenocysteine insertion into TXNRD1 |
| NFS1 | Cysteine desulfurase; iron-sulfur cluster and selenium metabolism | Redox homeostasis; ferroptosis |
| GCLC | Glutamate-cysteine ligase catalytic subunit | Glutathione synthesis; redox balance |
| GCLM | Glutamate-cysteine ligase modifier subunit | Glutathione synthesis; redox balance |
| SLC3A2 | Cystine transporter subunit | Cystine uptake; disulfidptosis |
| AKR1C1 | Aldo-keto reductase; redox regulation | Cellular stress response |
| TP53 | Tumor suppressor; regulates redox genes | Cancer context; redox signaling |
| KEAP1 | Negative regulator of Nrf2 | Controls TXNRD1 expression |
How Is thioredoxin-disulfide reductase complex Regulated?
The thioredoxin-disulfide reductase complex is regulated transcriptionally by Nrf2 (NFE2L2), which binds antioxidant response elements in the TXNRD1 promoter under oxidative stress. KEAP1 negatively regulates Nrf2, thereby indirectly controlling TXNRD1 levels. Post-translational regulation includes oxidation of the catalytic selenocysteine, which can be reversed by reducing systems. Substrate availability, particularly NADPH generated by the pentose phosphate pathway, limits flux through the complex. In cancer cells, oncogenic signaling and metabolic reprogramming often increase TXNRD1 expression to maintain redox balance.
thioredoxin-disulfide reductase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TXNRD1 | Glioblastoma; disulfidptosis sensitivity | CRISPR knockout in glioblastoma cell lines under glucose starvation |
| TXNRD1 | Ferroptosis regulation via GPX4 | Overexpression and point-mutation models in cancer cells |
| TXNRD2 | Mitochondrial dysfunction; apoptosis | Mitochondria-targeted knockout models |
| GPX4 | Ferroptosis; lipid peroxidation | Knock-in reporter for GPX4 expression |
| SLC7A11 | Disulfidptosis; cystine transport | Knockout and overexpression in cancer cells |
Cancer and Therapeutic Targeting
Thioredoxin-disulfide reductase complex activity is elevated in many cancers, where it protects cells from oxidative stress and supports proliferation. Pharmacological inhibitors, including gold(III) complexes and chiral compounds, have shown cytotoxic activity by targeting the selenocysteine residue. Patent reviews document extensive efforts to develop thioredoxin reductase inhibitors as anticancer agents. In glioblastoma, TXNRD1 inhibition sensitizes glucose-starved cells to disulfidptosis, suggesting a metabolic vulnerability.
Ferroptosis and Cell Death Regulation
TXNRD1 promotes ferroptosis by suppressing GPX4 expression, revealing a complex relationship between thioredoxin reductase and iron-dependent cell death. This finding has implications for cancers that are resistant to conventional apoptosis. Modulating the thioredoxin-disulfide reductase complex may therefore shift cell death programs and overcome therapy resistance.
Infectious Disease and Host-Pathogen Interactions
A paired analysis of host and pathogen genomes identified determinants of human tuberculosis, highlighting the role of redox-related genes in infection outcomes. While the exact contribution of the thioredoxin-disulfide reductase complex requires further study, redox homeostasis is known to influence immune cell function and pathogen survival.
Mitochondrial Dysfunction and Neurodegeneration
Mitochondria-targeting anticancer metal complexes often act on thioredoxin reductase, linking the complex to mitochondrial redox balance. In neurodegenerative conditions, oxidative stress and mitochondrial dysfunction are common features, and maintaining thioredoxin reductase activity may be protective. However, direct evidence for causal roles in neurodegeneration remains limited and requires further investigation.
From thioredoxin-disulfide reductase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TXNRD1 loss cause disulfidptosis? | CRISPR knockout in glucose-starved cancer cells |
| Does TXNRD1 regulate GPX4 expression? | Overexpression and knockdown models |
| What is the role of the selenocysteine residue? | Point mutation of the UGA codon in TXNRD1 |
| How does the complex localize in mitochondria? | Tagged knock-in of TXNRD2 with fluorescent protein |
| Can thioredoxin reductase inhibitors be tested genetically? | CRISPR knockout of TXNRD1 followed by drug treatment |
| What are the host determinants of tuberculosis? | Paired host-pathogen genome analysis and knockout models |
How to Study the thioredoxin-disulfide reductase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene essentiality and drug sensitivity | Identifying synthetic lethal partners of TXNRD1 |
| Redox proteomics | Thiol oxidation state of thioredoxin and peroxiredoxins | Assessing complex activity in cells |
| NADPH/NADP+ assay | Cellular reducing power | Measuring metabolic impact of complex inhibition |
| Lipid peroxidation assay | Ferroptosis induction | Evaluating GPX4-dependent cell death |
| Disulfide stress assay | Disulfidptosis activation | Glucose starvation studies |
| Immunoblotting | TXNRD1 protein levels and modifications | Validating knockout or overexpression |
| Live-cell imaging | Subcellular localization of tagged complex | Mitochondrial vs cytosolic dynamics |
| Selenocysteine insertion assay | Efficiency of UGA recoding | Studying TXNRD1 maturation |
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to thioredoxin reductase inhibitors or glucose starvation. Such screens have revealed TXNRD1 as a key vulnerability in glioblastoma under metabolic stress. Libraries targeting redox genes can be used to map synthetic lethal interactions with the thioredoxin-disulfide reductase complex.
Proteomics and Redox Proteomics
Mass spectrometry-based proteomics can quantify TXNRD1 protein levels and identify post-translational modifications, including oxidation of the selenocysteine residue. Redox proteomics using thiol-reactive probes can measure the reduced state of thioredoxin and peroxiredoxins, providing a readout of complex activity.
Metabolic and Cell Death Assays
NADPH/NADP+ ratios, glutathione levels, and lipid peroxidation markers (e.g., malondialdehyde, 4-HNE) are used to assess the impact of thioredoxin-disulfide reductase complex perturbation. Disulfidptosis and ferroptosis are distinguished using specific inhibitors (e.g., ferrostatin-1, erastin) and by monitoring disulfide stress.
Imaging and Subcellular Localization
Fluorescent tagging of TXNRD1 or TXNRD2 allows live-cell imaging of complex localization and dynamics. Mitochondria-targeted probes can assess redox state in specific compartments, linking complex activity to organelle function.
How CRISPR Can Be Used to Study GO:1902515 thioredoxin-disulfide reductase complex
Knockout
CRISPR knockout of TXNRD1 or TXNRD2 abolishes thioredoxin-disulfide reductase complex activity, leading to increased oxidative stress and altered cell death sensitivity. Knockout models have been used to show that TXNRD1 loss sensitizes glioblastoma cells to disulfidptosis under glucose starvation. These models are essential for distinguishing catalytic from non-catalytic functions of the complex.
Point Mutation
Point mutations can be introduced into the catalytic cysteine or selenocysteine codons of TXNRD1 to dissect the electron transfer mechanism. For example, mutating the UGA selenocysteine codon to cysteine reduces catalytic efficiency and alters inhibitor sensitivity. Such models help define the precise residues required for thioredoxin reduction.
Knock-in
Knock-in of fluorescent or affinity tags into endogenous TXNRD1 or TXNRD2 loci enables real-time tracking of complex localization and interaction partners. Tagged knock-in models are valuable for imaging studies and for immunoprecipitation of the complex under native conditions.
Overexpression
Overexpression of TXNRD1 or TXNRD2 increases thioredoxin-disulfide reductase complex activity and can protect cells from oxidative stress. Overexpression models have been used to demonstrate that TXNRD1 suppresses GPX4 expression and promotes ferroptosis. These models are useful for testing whether increased complex activity is sufficient to drive a phenotype.
How EDITGENE Supports thioredoxin-disulfide reductase complex Research
Researchers studying thioredoxin-disulfide reductase complex-related genes often need to determine whether a candidate gene is causally involved in redox regulation, cell death, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for thioredoxin-disulfide reductase complex research.
Frequently Asked Questions About thioredoxin-disulfide reductase complex
What is GO:1902515?
GO:1902515 is the Gene Ontology term for thioredoxin-disulfide reductase complex, a protein complex capable of thioredoxin-disulfide reductase activity.
What genes are involved in thioredoxin-disulfide reductase complex?
Key genes include TXNRD1, TXNRD2, TXN, TXN2, and related redox genes such as PRDX1, GPX4, and SLC7A11.
What does thioredoxin-disulfide reductase complex do?
It uses NADPH to reduce oxidized thioredoxin, maintaining cellular redox homeostasis and supporting antioxidant defense.
Why is thioredoxin-disulfide reductase complex important in cancer?
Many cancers overexpress TXNRD1 to cope with oxidative stress, and inhibiting the complex can trigger cell death, making it a therapeutic target.
How is thioredoxin-disulfide reductase complex regulated?
It is regulated transcriptionally by Nrf2, post-translationally by oxidation of its selenocysteine residue, and by NADPH availability.
What diseases are linked to thioredoxin-disulfide reductase complex?
It is linked to cancer, ferroptosis, disulfidptosis, mitochondrial dysfunction, and infectious diseases such as tuberculosis.
What methods are used to study thioredoxin-disulfide reductase complex?
CRISPR screening, redox proteomics, NADPH assays, lipid peroxidation assays, and live-cell imaging are commonly used.
Can CRISPR knockout be used to study TXNRD1?
Yes, CRISPR knockout of TXNRD1 is a powerful approach to assess its role in disulfidptosis and ferroptosis.
What is the role of selenocysteine in thioredoxin-disulfide reductase complex?
Selenocysteine is a catalytic residue in TXNRD1 that accelerates electron transfer and is targeted by inhibitors.
How does thioredoxin-disulfide reductase complex relate to ferroptosis?
TXNRD1 promotes ferroptosis by suppressing GPX4 expression, linking the complex to iron-dependent lipid peroxidation.
Conclusion
The thioredoxin-disulfide reductase complex (GO:1902515) is a central redox-regulatory machine with broad implications for cancer, cell death, and infectious disease. Its catalytic subunit TXNRD1 is a validated drug target, and recent studies have revealed unexpected roles in ferroptosis and disulfidptosis. Despite this progress, the causal contribution of individual complex components to disease remains incompletely defined. CRISPR-based knockout, point mutation, knock-in, and overexpression models offer the precision needed to move from correlation to causation. EDITGENE provides end-to-end services to generate such models, accelerating research on this critical complex.
References
- 1. Tang M et al.. 2025. Inhibition of thioredoxin reductase 1 sensitizes glucose-starved glioblastoma cells to disulfidptosis.. Cell Death Differ 32(4):598-612 PMID: 39715824
- 2. Chen M et al.. 2024. Chirality-driven strong thioredoxin reductase inhibition.. Biomaterials 311:122705 PMID: 39047537
- 3. Luo Y et al.. 2024. Paired analysis of host and pathogen genomes identifies determinants of human tuberculosis.. Nat Commun 15(1):10393 PMID: 39613754
- 4. Zhang B et al.. 2017. Thioredoxin reductase inhibitors: a patent review.. Expert Opin Ther Pat 27(5):547-556 PMID: 27977313
- 5. Chupakhin E et al.. 2021. Thioredoxin reductase inhibitors: updated patent review (2017-present).. Expert Opin Ther Pat 31(8):745-758 PMID: 33666133
- 6. Abyar F et al.. 2020. New cyclometalated gold (III) complex targeting thioredoxin reductase: exploring as cytotoxic agents and mechanistic insights.. Biometals 33(2-3):107-122 PMID: 32246384
- 7. Luan J et al.. 2026. Selenoprotein thioredoxin reductase 1 promotes cancer cells ferroptosis by suppressing GPX4 expression.. Cell Death Differ 33(9):1829-1845 PMID: 41748901
- 8. Erxleben A. 2019. Mitochondria-Targeting Anticancer Metal Complexes.. Curr Med Chem 26(4):694-728 PMID: 29521200
